PolyXite ΓÇô Multiparticulate Oral Dosage Form
- Increased bioavailability for orally administered drugs- Better distribution in the GIT ΓÇô therefore less likely to cause local irritation-Reduced risk of systemic toxicity.- Less dependent on gastric emptying - resulting in less subject variability in gastrointestinal transit time and dietary state.- No need for enteric coating due to the use of an enterosoluble particle matrix
PolyXite technology can be used as a once-daily, multi-unit drug delivery product, incorporating multiple drugs and significantly improving performance in terms of patient compliance, safety, and efficacy, thereby increasing the market share of existing drugs
PolyXite is an oral, multiparticulate system that comprises multiple sets of gastrosoluble and enterosoluble particles that are loaded with active pharmaceutical ingredients (APIs) and release-controlling polymers which control the site of API delivery. It is manufactured through ionic crosslinking of an enterosoluble polymer and enclosed within a single capsule. PolyXite enhances the efficiency of oral drug administration by presenting an oral dosage form that offers a reduction in the dose frequency and can be used to target a particular section of the GIT. The design of the technology also overcomes the challenges currently faced in the manufacturing of multiparticulate dosage forms associated with weight variation, poor hardness, and friability.PolyXite technology encapsulates the APIs within a polymeric matrix which is not dissolved in the upper GIT, and consequently, passes through the upper GIT and into the lower GIT where it is dissolved and the API is released. In combination therapy, PolyXite technology can also include a set of gastrosoluble particles for separating interacting drugs allowing them to be released in different areas of the GIT at a constant rate. This increases the bioavailability of the drugs as well as the rate and extent to which the drug is absorbed and made available.
美国
